gastric cancer with peritoneal metastasis
Conditions
Interventions
Paclitaxel is administered intravenously at 50 mg/m2 and intraperitoneally at 20 mg/m2 on days 1 and 8. S-1 is administered at 80 mg/m2/day for 14 consecutive days, followed by 7 days rest.
Sponsors
Department of Surgical Oncology, The University of Tokyo
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Histologically proven unresectable or recurrent gastric adenocarcinoma; peritoneal metastasis and/or cancer cells on peritoneal cytology; age more than 20 years; Eastern Cooperative Oncology Group performance status 0-2; adequate bone marrow function (leukocyte count 3,000-12,000/mm3, hemoglobin >8.0 g/dl, platelet count >100,000/mm3); adequate liver function (total serum bilirubin <1.5 mg/dl, serum transaminases <100/UI); adequate renal function (serum creatinine within the upper limit of normal); and an expected survival period of more than 3 months.
Exclusion criteria
Exclusion criteria: Metastasis to distant organ sites (such as the liver, lungs or bone), other active concomitant malignancies, or other severe medical conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the 1-year overall survival rate | — |
Secondary
| Measure | Time frame |
|---|---|
| the overall response rate, efficacy against peritoneal metastasis and safety | — |
Countries
Japan
Contacts
Public ContactHironori Ishigami
The University of Tokyo Department of Surgical Oncology
Outcome results
None listed